← FDA DRUG APPROVALS

FDA ANDA · ANDA062844

NAFCILLIN SODIUM

Sponsor: WATSON LABS INC

APPLICATION
ANDA062844
TYPE
ANDA
ORIGINAL APPROVAL
1988-10-26
LATEST ACTION
2000-12-08
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

NAFCILLIN SODIUMDiscontinued
NAFCILLIN SODIUM EQ 4GM BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMDiscontinued
NAFCILLIN SODIUM EQ 1.5GM BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMDiscontinued
NAFCILLIN SODIUM EQ 500MG BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMDiscontinued
NAFCILLIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
NAFCILLIN SODIUMDiscontinued
NAFCILLIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2000-12-08Manufacturing (CMC) · Supplement 18AP
1997-12-29Manufacturing (CMC) · Supplement 15AP
1996-03-22Labeling · Supplement 13AP
1995-12-15Manufacturing (CMC) · Supplement 14AP
1995-01-27Manufacturing (CMC) · Supplement 12AP
1994-01-13Manufacturing (CMC) · Supplement 11AP
1993-12-02Manufacturing (CMC) · Supplement 10AP
1993-11-09Manufacturing (CMC) · Supplement 9AP
1993-02-16Manufacturing (CMC) · Supplement 6AP
1990-11-07Manufacturing (CMC) · Supplement 4AP
1988-12-07Manufacturing (CMC) · Supplement 3AP
1988-11-10Manufacturing (CMC) · Supplement 2AP
1988-11-08Manufacturing (CMC) · Supplement 1AP
1988-10-26OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →